Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Eva Medvedova et al.|New England Journal of Medicine|2022Cited by 457
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).Sham Mailankody, Sandy W. Wong, Andrzej Jakubowiak et al.|Journal of Clinical Oncology|2020Cited by 122
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trialAttaya Suvannasankha, Alexander M. Lesokhin, Jonathan L. Kaufman et al.|Blood|2025Cited by 6